Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR

References

• VakilNvan ZantenSVKahrilasPDentJJonesRGlobal ConsensusGThe Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensusAm J Gastroenterol200610119001920 quiz 4316928254
   PubMed Web of Science ®Google Scholar
• El-SeragHBSweetSWinchesterCCDentJUpdate on the epidemiology of gastro-oesophageal reflux disease: a systematic reviewGut20146387188023853213
   PubMed Web of Science ®Google Scholar
• DentJEl-SeragHBWallanderMAJohanssonSEpidemiology of gastro-oesophageal reflux disease: a systematic reviewGut20055471071715831922
   PubMed Web of Science ®Google Scholar
• BoeckxstaensGEl-SeragHBSmoutAJKahrilasPJSymptomatic reflux disease: the present, the past and the futureGut2014631185119324607936
   PubMed Web of Science ®Google Scholar
• BecherADentJSystematic review: ageing and gastro-oesophageal reflux disease symptoms, oesophageal function and reflux oesophagitisAliment Pharmacol Ther20113344245421138458
   PubMed Web of Science ®Google Scholar
• KahrilasPJShaheenNJVaeziMFAmerican Gastroenterological Association Medical Position Statement on the management of gastroe-sophageal reflux diseaseGastroenterology2008135138313911391e1e518789939
   PubMed Web of Science ®Google Scholar
• KatzPOGersonLBVelaMFGuidelines for the diagnosis and management of gastroesophageal reflux diseaseAm J Gastroenterol2013108308328 quiz 2923419381
   PubMed Web of Science ®Google Scholar
• CheyWDModyRRIzatEPatient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?Dig Dis Sci2010553415342220397047
   PubMed Web of Science ®Google Scholar
• CheyWDModyRRWuEQTreatment patterns and symptom control in patients with GERD: US community-based surveyCurr Med Res Opin2009251869187819530980
   PubMed Web of Science ®Google Scholar
• KatzPOScheimanJMBarkunANReview article: acid-related disease – what are the unmet clinical needs?Aliment Pharmacol Ther200623suppl 292216700899
   PubMed Web of Science ®Google Scholar
• ShinJMKimNPharmacokinetics and pharmacodynamics of the proton pump inhibitorsJ Neurogastroenterol Motil201319253523350044
   PubMed Web of Science ®Google Scholar
• GohKLChoiMGHsuWPUnmet treatment needs of gastroe-sophageal reflux disease in Asia: gastroesophageal reflux disease in Asia Pacific SurveyJ Gastroenterol Hepatol2014291969197524990817
   PubMed Web of Science ®Google Scholar
• SchubertMLPeuraDAControl of gastric acid secretion in health and diseaseGastroenterology20081341842186018474247
   PubMed Web of Science ®Google Scholar
• BehmBWPeuraDADexlansoprazole MR for the management of gastroesophageal reflux diseaseExpert Rev Gastroenterol Hepatol2011543944521780890
   PubMed Web of Science ®Google Scholar
• KatsukiHYagiHArimoriKDetermination of R(+)- and S(−)- lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humansPharm Res1996136116158710755
   PubMed Web of Science ®Google Scholar
• AbelCDesiletsARWillettKDexlansoprazole in the treatment of esophagitis and gastroesophageal reflux diseaseAnn Pharmacother20104487187720371754
   PubMed Web of Science ®Google Scholar
• WittbrodtETBaumCPeuraDADelayed release dexlansoprazole in the treatment of GERD and erosive esophagitisClin Exp Gastroenterol2009211712821694835
   PubMedGoogle Scholar
• FassRCheyWDZakkoSFClinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux diseaseAliment Pharmacol Ther2009291261127219392864
   PubMed Web of Science ®Google Scholar
• VakilyMZhangWWuJAtkinsonSNMulfordDPharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trialsCurr Med Res Opin20092562763819232037
   PubMed Web of Science ®Google Scholar
• KukulkaMEisenbergCNudurupatiSComparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mgClin Exp Gastroenterol2011421322022016582
   PubMedGoogle Scholar
• MetzDCHowdenCWPerezMCLarsenLO’NeilJAtkinsonSNClinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitisAliment Pharmacol Ther20092974275419210298
   PubMed Web of Science ®Google Scholar
• LeeRDVakilyMMulfordDWuJAtkinsonSNClinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor – evidence for dosing flexibilityAliment Pharmacol Ther20092982483319243357
   PubMed Web of Science ®Google Scholar
• LeeRDMulfordDWuJAtkinsonSNThe effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a dual delayed release proton pump inhibitorAliment Pharmacol Ther2010311001101120180789
   PubMed Web of Science ®Google Scholar
• PeuraDAMetzDCDabholkarAHParisMMYuPAtkinsonSNSafety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experienceAliment Pharmacol Ther2009301010102119735233
   PubMed Web of Science ®Google Scholar
• FrelingerAL3rdLeeRDMulfordDJA randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteersJ Am Coll Cardiol2012591304131122464259
   PubMed Web of Science ®Google Scholar
• SharmaPShaheenNJPerezMCClinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation – results from two randomized controlled studiesAliment Pharmacol Ther20092973174119183157
   PubMed Web of Science ®Google Scholar
• WuMSTanSCXiongTIndirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs esomeprazole in the treatment of gastro-oesophageal reflux diseaseAliment Pharmacol Ther20133819020123718547
   PubMed Web of Science ®Google Scholar
• PeuraDAPilmerBHuntBModyRPerezMCThe effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazoleAliment Pharmacol Ther20133781081823451835
   PubMed Web of Science ®Google Scholar
• FassRJohnsonDAOrrWCThe effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERDAm J Gastroenterol201110642143121224838
   PubMed Web of Science ®Google Scholar
• FassRInadomiJHanCModyRO’NeilJPerezMCMaintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified releaseClin Gastroenterol Hepatol20121024725322155561
   PubMed Web of Science ®Google Scholar
• KahrilasPJHowdenCWHughesNResponse of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux diseaseAm J Gastroenterol201110614191425 quiz 2621537361
   PubMed Web of Science ®Google Scholar
• PeuraDAPilmerBHuntBModyRPerezMCDistinguishing the impact of dexlansoprazole on heartburn vs regurgitation in patients with gastro-oesophageal reflux diseaseAliment Pharmacol Ther2013381303131124118079
   PubMed Web of Science ®Google Scholar
• AttumiTAGrahamDYHigh-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infectionsHelicobacter20141931932224698653
   PubMed Web of Science ®Google Scholar
• YangJCLinCJWangHLHigh-dose dual therapy is superior to standard first-line or rescue therapy for helicobacter pylori infectionClin Gastroenterol Hepatol201413589590525460556
   PubMed Web of Science ®Google Scholar